Year: 2026 | Month: September | Volume: 13 | Issue: 9 | Pages: 463-469
DOI: https://doi.org/10.52403/ijrr.20260944
Safety of Remdesivir in COVID-19-Infected Patients with End-Stage Renal Disease on Haemodialysis: An Observational Study at a Tertiary Care Hospital, 2021–2022
Sankeerthana Gajjala1, Anusha Gudipati2, Aayushi Jaiswal3, Diwakar Naidu G4, Pasupulati Haritha5
1Research Associate, Hyderabad, India
2Independent Researcher, Columbia, USA
3Research Consultant, Hyderabad, India
4Consultant Nephrologist, Hyderabad, India
5Associate Professor, Department of Pharmacology, Bharat Institute of Technology (BIT-Pharmacy), Hyderabad, India
Corresponding Author: Sankeerthana Gajjala
ABSTRACT
Background: The COVID-19 pandemic, caused by SARS-CoV-2, presents a global health crisis. Patients with End-Stage Renal Disease (ESRD) on haemodialysis are particularly vulnerable to severe COVID-19. This study evaluates the safety of remdesivir, a potential treatment for COVID-19, in this high-risk population.
Methods: This retrospective observational study was conducted over five months (March-July 2021) at a tertiary care hospital. It included 140 adult patients with ESRD on haemodialysis who were infected with COVID-19; 94 received remdesivir, and 46 did not. Data was collected from patient records, and liver function tests and adverse drug reaction reports were the primary parameters assessed. Secondary parameters included oxygen requirement and length of hospital stay.
Results: Remdesivir was generally well-tolerated. The mean age of the patients was 46.7 years. Hypertension was the most common comorbidity. The mean length of hospital stay was 5.75 days for the remdesivir group and 2.56 days for the non-remdesivir group. The 30-day mortality rate in the remdesivir group was 4.25%, and 4.34% in the non-remdesivir group. Significant differences post-treatment were observed in lymphocytes, D-dimer, and serum creatinine levels.
Conclusion: Remdesivir demonstrates a potential for safe administration in COVID-19-infected ESRD patients undergoing haemodialysis. Further research is needed to establish its efficacy and long-term outcomes in this population.
Keywords: COVID-19, Remdesivir, End-Stage Renal Disease, Haemodialysis, Safety, Retrospective Study
[PDF Full Text]